Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$0.0 - $1.94 $0 - $4.29 Million
-2,210,056 Reduced 76.74%
669,944 $0
Q1 2023

May 12, 2023

BUY
$0.9 - $1.85 $2.59 Million - $5.33 Million
2,880,000 New
2,880,000 $5.33 Million

Others Institutions Holding JNCE

About Jounce Therapeutics, Inc.


  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Opaleye Management Inc. Portfolio

Follow Opaleye Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.